Resources

How recent British Business Bank commitments and BIA member milestones are keeping UK life sciences momentum strong

Chris Molloy on mRNA cancer vaccine reaching Phase 3 milestone, Scancell MHRA authorisation, microbiome-based medicinal products, MHRA voucher scheme for SMEs, Scotland and data driver projects

Claire Smith, who sits on BIA’s Intellectual Property Advisory Committee (IPAC) committee, and James Johnston explain what the US BIOSECURE Act means for UK biotech companies

Chris Molloy on Mike Hoare, the RedX-Skye deal, Stablepharma’s fridge-free vaccine, MHRA quarterly numbers, ministerial responsibilities for UK life sciences and human biology-based models

Celebrating trailblazing biotech founders

AI may be biotech’s biggest opportunity, but without the right data infrastructure, even the smartest models risk getting stuck at pilot stage

BIA Annual General Meeting 2026: nominations open for BIA Board election

Tanya Bos, Non-Executive Director at BioSci Toolkit CIC, discusses securing her first NED role as part of the She Steers programme

Join the delegation as BIA boosts UK presence at BioShanghai in September

The advantages to building a business in the UK's biotech clusters

Each month, our Policy and Public Affairs team will showcase how we are championing members’ voices in Government and Parliament.

Chris Molloy on new pension scale-up fund news, member news from Touchlight, the major GSK investment in Cambridge, a valuable collaboration for Relation and BIA's parliamentary engagement

Biosolutions are a billion-pound national asset delivering growth in every region of the UK

Chris Molloy on what the new Government means for the sector, a farewell to Lord Patrick Vallance, gene synthesis screening and TechBio UK early bird tickets

From first-in-class approvals to billion-dollar deals, Q2 2026 signals a new era for antibody innovation

Chris Molloy on the Q2 2026 finance report, investment in Draig Therapeutics, MHRA meeting, centure capital summit and upcoming BIA events

Solena Materials is a pioneering biotech company specialising in computationally-designed synthetic protein materials

How to unlock the UK's innovative life sciences and biotech potential

Jane Wall discusses investment in Alchemab Therapeutics, Life Sciences Sector Plan: one year on, regulatory and trade links, Women in Biotech and BIA members lounge

How we boost entry-level diversity up to the senior level